Search results
UK Markey Cancer Center is expanding a key program, but losing its architect
Lexington Herald-Leader McClatchy via AOL· 6 days agoUniversity of Kentucky’s precision medicine tailors treatment to individual patients by taking into...
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab,...
The Pilot News· 5 days agoSugemalimab is expected to become the first anti-PD-L1 monoclonal antibody (mAb) in the world approved in Europe for both first-line squamous and non-squamous NSCLC, regardless of PD-L1...
The MUHC Foundation’s Le Bal Rouge Gala Raises a record-breaking $2,050,000 million for Cancer...
Digital Journal· 3 days agoThe MUHC Foundation backs the most innovative cancer researchers in the province. This year’s Le Bal Rouge gala supported the Cancer Research Program of ...
Once-Popular Seasonings People Stopped Using
Mashed via Yahoo News· 14 hours agoThey are also known to lower cholesterol, they may have cancer-fighting properties, and they can help kill off harmful bacteria in the body. Because of...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 3 days agoCARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO PR Newswire SHANGHAI, June 4, 2024 SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics ...
In Treating IBD, Consider Diet and Dentistry
Medscape· 2 days agoDr David Johnson highlights five compelling studies from this year's Digestive Disease Week exploring the role of oral health, diet, and intestinal...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoRNAi Therapeutics and Technology Market Worth USD 5.36 Billion by 2031 at 16.6% CAGR- Exclusive Report by InsightAce Analytic Pvt. Ltd. PR Newswire JERSEY CITY, N.J., June 4, 2024 JERSEY CITY, N.J., June 4, 2024 /PRNewswire/ -- InsightAce Analytic
Key Endoscopy Studies That Could Transform Your Practice
Medscape· 7 days agoDr David Johnson provides insight on 11 studies from this year's Digestive Disease Week, including...
LDT Final Rule Series: Part 2 – Response to the Rule
The National Law Review· 5 hours agoIn this second installment of our nine-part deep-dive into the U.S. Food & Drug Administration (“FDA” or “the Agency”) final rule on Laboratory Developed...
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R)...
Digital Journal· 4 days agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
